EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial

Sheng-Ting Zhang, Hong-Yi Tan, Shuang Yang, Xiao-Yan Yang, Chang Cui, Jie Huang, Guo-Ping Yang

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03705-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Sheng-Ting Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmacy, Central South University, Changsha, 410013, Hunan, China. Hauptthemen laut MEDLINE: Receptors, Calcium-Sensing. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Provincial Natural Science Foundation of China, Shanghai Hengrui Biotech, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of SHR6508 injection, a new calcimimetic agent, in healthy Chinese subjects following single dose. This study utilized a placebo-controlled, single-dose, and dose-escalation design with four dose groups (0.5 mg, 2.5 mg, 5 mg, 10 mg). The trial started with a low dose and continuing to the next dose after completion of the out-of-group safety assessment of the previous dose group. Blood samples were collected at 15 time points to measure pharmacokinetic and pharmacodynamic parameters. Safety was assessed by therapeutic emergency adverse events (TEAEs), clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical examination. Of the 22 subjects who completed this study, 16 received SHR6508 Injection and 6 received placebo. In the 0.5-5 mg group, t1/2z was 8.8 h-28.3 h. Cmax and AUC increased proportionally with dose. PD results showed that SHR6508 dose dependently decreased iPTH and blood calcium levels in subjects in the 0.5-5-mg dose range; blood phosphorus levels in subjects in the 5 mg group tended to be elevated compared to those in the placebo group. Twenty-one TEAEs occurred in 12 subjects (54.5%), and no serious or severe TEAEs occurred. The overall safety and tolerability of a single intravenous dose of 0.5-5 mg SHR6508 in healthy subjects was favorable, exhibiting dose-dependent PK and PD properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Calcium-SensingAdultFemaleHumansMaleMiddle AgedYoung AdultCalciumChinaDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHyperparathyroidism, Secondary

Stichwörter der Autor:innen

Calcimimetic agentsChronic kidney diseaseSafetySecondary hyperparathyroidism

Substanzen

CalciumReceptors, Calcium-Sensing

Autor:innen und Institutionen

  • Xiangya School of Pharmacy, Central South University, Changsha, 410013, Hunan, China.
  • Center of Clinical Pharmacology, The Third, Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China.
  • Center of Clinical Pharmacology, The Third, Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China. cellahuang1988@163.com.
  • Xiangya School of Pharmacy, Central South University, Changsha, 410013, Hunan, China. ygp9880@126.com.
  • Center of Clinical Pharmacology, The Third, Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China. ygp9880@126.com.

Förderung

  • Hunan Provincial Natural Science Foundation of China
  • Shanghai Hengrui Biotech, Inc.

Zitieren

APA

Zhang, S. T., Tan, H. Y., Yang, S., Yang, X. Y., Cui, C., Huang, J., & Yang, G. P. (2025). The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03705-4

Vancouver

Zhang ST, Tan HY, Yang S, Yang XY, Cui C, Huang J, et al. The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03705-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Sheng-Ting and Tan, Hong-Yi and Yang, Shuang and Yang, Xiao-Yan and Cui, Chang and Huang, Jie and Yang, Guo-Ping},
  title = {The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03705-4}
}
Kostenlos starten →